Tauvid FDA Approval History
Last updated by Judith Stewart, BPharm on June 25, 2020.
FDA Approved: Yes (First approved May 28, 2020)
Brand name: Tauvid
Generic name: flortaucipir F 18
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Diagnosis and Investigation
Tauvid (flortaucipir F 18) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).
Development timeline for Tauvid
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
